HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS
申请人:Berger Richard
公开号:US20110028461A1
公开(公告)日:2011-02-03
The present invention provides compounds of Formula I, pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.
Korotkikh, N. I.; Artemov, V. N.; Shvaika, O. P., Doklady Chemistry, 1986, vol. 290, p. 375 - 378
作者:Korotkikh, N. I.、Artemov, V. N.、Shvaika, O. P.
DOI:——
日期:——
KOROTKIX N. I.; ARTEMOV V. N.; SHVAJKA O. P., DOKL. AN CCCP, 290,(1986) N 3, 624-627
作者:KOROTKIX N. I.、 ARTEMOV V. N.、 SHVAJKA O. P.
DOI:——
日期:——
Neurokinin-1 Receptor Antagonists For Use In A Method Of Prevention Of Cancer
申请人:ONCOPREVENT GMBH
公开号:US20160324881A1
公开(公告)日:2016-11-10
Subject matter of the present invention is a neurokinin-1 receptor antagonist for use in a method of prevention of cancer.
Particularly, subject matter of the present invention is a neurokinin-1 receptor antagonist according to the compounds of Formula (I) or a tautomer thereof or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable salt of a tautomer thereof for use in a method of preventing cancer. In a very specific embodiment the non-peptide antagonist fosaprepitant sir aprepitant is said neurokinin-1 receptor antagonist. In another specific embodiment, subject matter of the present invention is a neurokinin-1 receptor antagonist for use in a method of preventing cancer as monotherapeutic agent.